Discovery of an Injectable Protein Targeting Leaky Gut and Depression

A Protein-Based Link Between Gut Health and Depression

Emerging research from the University of Victoria, published in the journal Chronic Stress, highlights the potential of a naturally occurring glycoprotein called Reelin as a future therapeutic option for both gastrointestinal dysfunction and depression.

Chronic Stress and the “Leaky Gut” Phenomenon

In a healthy body, the gastrointestinal tract—which includes the stomach, intestines, and colon - acts as a selective barrier. It allows essential nutrients to pass into the bloodstream while preventing harmful substances from entering circulation. However, prolonged exposure to chronic stress can disrupt this balance.

Under stress-related conditions such as major depressive disorder (MDD), the gut barrier may become excessively permeable, a condition commonly referred to as “leaky gut.” When this happens, bacteria and toxins can cross into the bloodstream, triggering immune responses and inflammation. These inflammatory processes are believed to worsen depressive symptoms, reinforcing the link between gut health and mental health.

Understanding the Gut–Brain Axis

According to Hector Caruncho, professor of medical sciences and corresponding author of the study, the gut–brain axis plays a critical role in psychiatric disorders. Reelin, a protein widely distributed throughout the body—including the brain, blood, liver, and intestines - appears to be a key player in this connection.

The research focused on understanding how Reelin functions in the gut under conditions of chronic stress. Findings from preclinical models showed that ongoing stress significantly reduced Reelin levels in intestinal tissue. Remarkably, administering a single injection of Reelin restored these levels to normal.

Reelin’s Role in Depression and Gut Integrity

Earlier studies have demonstrated that individuals diagnosed with major depressive disorder exhibit reduced Reelin levels in the brain. Similar reductions have been observed in animal models exposed to chronic stress. Notably, a single intravenous dose of Reelin produced antidepressant-like effects in these models.

In addition to its neurological effects, Reelin has been shown to be essential for the renewal of the gut lining. Under healthy conditions, the cells lining the gut regenerate every four to five days - a process crucial for maintaining a strong barrier against harmful substances.

If Reelin supports this renewal process, it may help prevent gut leakage and reduce inflammation-driven worsening of depression. This dual action suggests that Reelin could protect mental health by simultaneously supporting gut integrity.

Implications for Future Treatment

Ciara Halvorson, the study’s first author and a neuroscience PhD candidate, notes that these findings may be especially relevant for individuals who experience both depression and gastrointestinal disorders. By targeting mechanisms in both the brain and the gut, Reelin-based therapies could represent a new, integrated approach to managing major depressive disorder.

While additional research is required before clinical applications become possible, this study positions Reelin as a promising candidate for future treatments that address depression through both neurological and gastrointestinal pathways.

The research was supported by funding from the Canadian Institutes of Health Research (CIHR) and the Natural Sciences and Engineering Research Council of Canada (NSERC).

Source: University of Victoria
ImageCredits: Freepik